Vasculitis & polymyalgia rheumatica
Tocilizumab in cranial and extracranial giant cell arteritis: a national multicentre study of 471 cases
Authors' conclusion
TCZ shows rapid and maintained effectiveness in all GCA phenotypes in clinical remission and EULAR complete remission. By contrast, absence of inflammation as shown using imaging techniques was much lower in ecGCA and mixGCA.
Study context
- Population
- GCA patients treated with tocilizumab (TCZ)342 women
- Participants
- 471 patients
- Exposure
- TCZ in cranial vs extracranial vs mixed GCA phenotypes
- cGCAn = 217
- Extracranial GCA (ecGCA)n = 80
- Mixed GCA (mixGCA)n = 174
- Outcome
- Clinical remission
- Follow-up
- 24 months
Methodological detailsnational
- National
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | ecGCA | mixGCA |
|---|---|---|
| Absence of inflammation on imaging · 24 months | 22% | 7% |
Absence of inflammation on imaging · 12 months
- Absence of inflammation shown in imaging techniques after 12 months (groups not named for this time point)
- 15%/26%
Safety
- Patients with relevant adverse events
- 109 (23.1%)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Tocilizumab in cranial and extracranial giant cell arteritis: a national multicentre study of 471 cases. Rheumatology (Oxford). Published 10 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →